• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病和非酒精性脂肪性肝炎中库普弗细胞的激活:机制与治疗干预

Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions.

作者信息

Xu Gao-Xin, Wei Song, Yu Chao, Zhao Si-Qi, Yang Wei-Jun, Feng Yong-Heng, Pan Chao, Yang Kun-Xing, Ma Yong

机构信息

Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.

出版信息

Front Cell Dev Biol. 2023 May 16;11:1199519. doi: 10.3389/fcell.2023.1199519. eCollection 2023.

DOI:10.3389/fcell.2023.1199519
PMID:37261074
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10228659/
Abstract

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are emerging as the leading causes of liver disease worldwide. These conditions can lead to cirrhosis, liver cancer, liver failure, and other related ailments. At present, liver transplantation remains the sole treatment option for end-stage NASH, leading to a rapidly growing socioeconomic burden. Kupffer cells (KCs) are a dominant population of macrophages that reside in the liver, playing a crucial role in innate immunity. Their primary function includes phagocytosing exogenous substances, presenting antigens, and triggering immune responses. Moreover, they interact with other liver cells during the pathogenesis of NAFLD, and this crosstalk may either delay or exacerbate disease progression. Stimulation by endogenous signals triggers the activation of KCs, resulting in the expression of various inflammatory factors and chemokines, such as NLRP3, TNF-α, IL-1B, and IL-6, and contributing to the inflammatory cascade. In the past 5 years, significant advances have been made in understanding the biological properties and immune functions of KCs in NAFLD, including their interactions with tissue molecules, underlying molecular mechanisms, signaling pathways, and relevant therapeutic interventions. Having a comprehensive understanding of these mechanisms and characteristics can have enormous potential in guiding future strategies for the prevention and treatment of NAFLD.

摘要

非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)正逐渐成为全球肝病的主要病因。这些病症可导致肝硬化、肝癌、肝衰竭及其他相关疾病。目前,肝移植仍是终末期NASH的唯一治疗选择,这导致社会经济负担迅速加重。库普弗细胞(KCs)是肝脏中占主导地位的巨噬细胞群体,在固有免疫中起关键作用。它们的主要功能包括吞噬外源性物质、呈递抗原和触发免疫反应。此外,在NAFLD发病机制中,它们与其他肝细胞相互作用,这种相互作用可能会延缓或加剧疾病进展。内源性信号刺激会触发KCs的激活,导致各种炎症因子和趋化因子的表达,如NLRP3、TNF-α、IL-1B和IL-6,并促成炎症级联反应。在过去5年里,在了解NAFLD中KCs的生物学特性和免疫功能方面取得了重大进展,包括它们与组织分子的相互作用、潜在分子机制、信号通路及相关治疗干预措施。全面了解这些机制和特征对于指导未来NAFLD的预防和治疗策略具有巨大潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff28/10228659/8e131e45b0a9/fcell-11-1199519-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff28/10228659/8e131e45b0a9/fcell-11-1199519-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff28/10228659/8e131e45b0a9/fcell-11-1199519-g001.jpg

相似文献

1
Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions.非酒精性脂肪性肝病和非酒精性脂肪性肝炎中库普弗细胞的激活:机制与治疗干预
Front Cell Dev Biol. 2023 May 16;11:1199519. doi: 10.3389/fcell.2023.1199519. eCollection 2023.
2
Major roles of kupffer cells and macrophages in NAFLD development.枯否细胞和巨噬细胞在非酒精性脂肪性肝病发展中的主要作用。
Front Endocrinol (Lausanne). 2023 May 19;14:1150118. doi: 10.3389/fendo.2023.1150118. eCollection 2023.
3
NLRP3 Deletion Inhibits the Non-alcoholic Steatohepatitis Development and Inflammation in Kupffer Cells Induced by Palmitic Acid.NLRP3 缺失抑制棕榈酸诱导的库普弗细胞非酒精性脂肪性肝炎发生和炎症反应。
Inflammation. 2017 Dec;40(6):1875-1883. doi: 10.1007/s10753-017-0628-z.
4
Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development.硫氧还蛋白相互作用蛋白对小鼠库普弗细胞中NLRP3炎性小体的抑制作用作为非酒精性脂肪性肝病发展的一种调节机制。
Oncotarget. 2017 Jun 6;8(23):37657-37672. doi: 10.18632/oncotarget.17489.
5
Cathepsin B inhibition ameliorates the non-alcoholic steatohepatitis through suppressing caspase-1 activation.组织蛋白酶 B 抑制通过抑制半胱氨酸天冬氨酸蛋白酶-1 的激活改善非酒精性脂肪性肝炎。
J Physiol Biochem. 2018 Nov;74(4):503-510. doi: 10.1007/s13105-018-0644-y. Epub 2018 Jul 17.
6
Cardiolipin inhibitor ameliorates the non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation.心磷脂抑制剂通过抑制 NLRP3 炎性小体的激活来改善非酒精性脂肪性肝炎。
Eur Rev Med Pharmacol Sci. 2019 Sep;23(18):8158-8167. doi: 10.26355/eurrev_201909_19036.
7
Targeting hepatic macrophages for non-alcoholic fatty liver disease therapy.以肝脏巨噬细胞为靶点治疗非酒精性脂肪性肝病
Front Cell Dev Biol. 2024 Sep 5;12:1444198. doi: 10.3389/fcell.2024.1444198. eCollection 2024.
8
Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.巨噬细胞衍生的血小板反应蛋白1促进肥胖相关的非酒精性脂肪性肝病。
JHEP Rep. 2020 Oct 9;3(1):100193. doi: 10.1016/j.jhepr.2020.100193. eCollection 2021 Feb.
9
The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.肝巨噬细胞在非酒精性脂肪性肝病和非酒精性脂肪性肝炎中的作用。
Lab Anim Res. 2018 Dec;34(4):133-139. doi: 10.5625/lar.2018.34.4.133. Epub 2018 Dec 31.
10
Treating inflammation to combat non-alcoholic fatty liver disease.治疗炎症以对抗非酒精性脂肪性肝病。
J Endocrinol. 2022 Dec 12;256(1). doi: 10.1530/JOE-22-0194. Print 2023 Jan 1.

引用本文的文献

1
Type 2 Diabetes and the Multifaceted Gut-X Axes.2型糖尿病与多维度的肠道-X轴
Nutrients. 2025 Aug 21;17(16):2708. doi: 10.3390/nu17162708.
2
Stage-specific role of IGFBP-3/TMEM219 pathway in liver fibrosis progression using a bile duct ligation rat model.利用胆管结扎大鼠模型研究IGFBP - 3/TMEM219通路在肝纤维化进展中的阶段特异性作用。
Mol Biol Rep. 2025 Aug 25;52(1):844. doi: 10.1007/s11033-025-10831-6.
3
Pathological Evolution and Internal Medicine Management of Nonalcoholic Fatty Liver Disease (NAFLD) in the Era of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

本文引用的文献

1
Exosomal RBP4 potentiated hepatic lipid accumulation and inflammation in high-fat-diet-fed mice by promoting M1 polarization of Kupffer cells.外泌体 RBP4 通过促进库普弗细胞 M1 极化促进高脂肪饮食喂养小鼠的肝脂质积累和炎症。
Free Radic Biol Med. 2023 Feb 1;195:58-73. doi: 10.1016/j.freeradbiomed.2022.12.085. Epub 2022 Dec 24.
2
S100A8-Mediated NLRP3 Inflammasome-Dependent Pyroptosis in Macrophages Facilitates Liver Fibrosis Progression.S100A8 介导的巨噬细胞 NLRP3 炎性小体依赖性细胞焦亡促进肝纤维化进展。
Cells. 2022 Nov 12;11(22):3579. doi: 10.3390/cells11223579.
3
Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications.
代谢功能障碍相关脂肪性肝病(MASLD)时代非酒精性脂肪性肝病(NAFLD)的病理演变与内科管理
Cureus. 2025 Jun 29;17(6):e86963. doi: 10.7759/cureus.86963. eCollection 2025 Jun.
4
Empagliflozin reduces liver fibrosis by restoring catechol-O-methyltransferase activity associated with magnesium levels.恩格列净通过恢复与镁水平相关的儿茶酚-O-甲基转移酶活性来减轻肝纤维化。
Sci Rep. 2025 Jul 26;15(1):27310. doi: 10.1038/s41598-025-12813-x.
5
The Role of Extracellular Vesicles in the Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease and Other Liver Diseases.细胞外囊泡在代谢功能障碍相关脂肪性肝病及其他肝脏疾病发病机制中的作用
Int J Mol Sci. 2025 May 23;26(11):5033. doi: 10.3390/ijms26115033.
6
Chronic Inflammation and Immune Dysregulation in Metabolic-Dysfunction-Associated Steatotic Liver Disease Progression: From Steatosis to Hepatocellular Carcinoma.代谢功能障碍相关脂肪性肝病进展中的慢性炎症与免疫失调:从脂肪变性到肝细胞癌
Biomedicines. 2025 May 21;13(5):1260. doi: 10.3390/biomedicines13051260.
7
Isoschaftoside in Fig Leaf Tea Alleviates Nonalcoholic Fatty Liver Disease in Mice via the Regulation of Macrophage Polarity.无花果叶茶中的异荭草苷通过调节巨噬细胞极化减轻小鼠非酒精性脂肪性肝病。
Nutrients. 2025 Feb 21;17(5):757. doi: 10.3390/nu17050757.
8
Effects of Selected Food Additives on the Gut Microbiome and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).所选食品添加剂对肠道微生物群及代谢功能障碍相关脂肪性肝病(MASLD)的影响
Medicina (Kaunas). 2025 Jan 22;61(2):192. doi: 10.3390/medicina61020192.
9
Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk.代谢功能障碍相关脂肪性肝病:与心血管风险的发病机制联系
Biomolecules. 2025 Jan 22;15(2):163. doi: 10.3390/biom15020163.
10
Pathogenetic development, diagnosis and clinical therapeutic approaches for liver metastasis from colorectal cancer (Review).结直肠癌肝转移的发病机制、诊断及临床治疗方法(综述)
Int J Oncol. 2025 Mar;66(3). doi: 10.3892/ijo.2025.5728. Epub 2025 Feb 14.
非酒精性脂肪性肝病中的肠道菌群失调:发病机制、诊断和治疗意义。
Front Cell Infect Microbiol. 2022 Nov 8;12:997018. doi: 10.3389/fcimb.2022.997018. eCollection 2022.
4
Pyruvate Dehydrogenase Kinase 2 Accelerates Endotoxin Shock by Promoting Mitogen-Activated Protein Kinase Activation.丙酮酸脱氢酶激酶2通过促进丝裂原活化蛋白激酶激活加速内毒素休克。
Inflammation. 2023 Feb;46(1):418-431. doi: 10.1007/s10753-022-01744-8. Epub 2022 Sep 29.
5
An Eye on Kupffer Cells: Development, Phenotype and the Macrophage Niche.关注库普弗细胞:发育、表型和巨噬细胞龛。
Int J Mol Sci. 2022 Aug 30;23(17):9868. doi: 10.3390/ijms23179868.
6
Gondoic acid alleviates LPS‑induced Kupffer cells inflammation by inhibiting ROS production and PKCθ/ERK/STAT3 signaling pathway.弓背酸内酯通过抑制 ROS 产生和 PKCθ/ERK/STAT3 信号通路缓解 LPS 诱导的枯否细胞炎症。
Int Immunopharmacol. 2022 Oct;111:109171. doi: 10.1016/j.intimp.2022.109171. Epub 2022 Aug 20.
7
Aberrant iron distribution via hepatocyte-stellate cell axis drives liver lipogenesis and fibrosis.异常的铁分布通过肝细胞-星状细胞轴驱动肝脏脂肪生成和纤维化。
Cell Metab. 2022 Aug 2;34(8):1201-1213.e5. doi: 10.1016/j.cmet.2022.07.006.
8
Lp2 improved LPS-induced liver injury through the TLR-4/MAPK/NFκB and Nrf2-HO-1/CYP2E1 pathways in mice.Lp2通过TLR-4/MAPK/NFκB和Nrf2-HO-1/CYP2E1信号通路改善小鼠脂多糖诱导的肝损伤。
Food Nutr Res. 2022 Jul 5;66. doi: 10.29219/fnr.v66.5459. eCollection 2022.
9
An overview of ferroptosis in non-alcoholic fatty liver disease.非酒精性脂肪性肝病中的铁死亡概述
Biomed Pharmacother. 2022 Sep;153:113374. doi: 10.1016/j.biopha.2022.113374. Epub 2022 Jul 11.
10
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.全球非酒精性脂肪性肝病的患病率和发病率:系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2022 Sep;7(9):851-861. doi: 10.1016/S2468-1253(22)00165-0. Epub 2022 Jul 5.